Who Owns AN2 Therapeutics Stock?
NASDAQ: ANTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 76.88%
- Held by insiders
- 15.98%
- Institutional holders
- 98
- Institutions 76.9%
- Insiders 16.0%
- Public and other 7.1%
Who owns AN2 Therapeutics stock?
Institutional investors own about 76.9% of AN2 Therapeutics's shares, spread across 98 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 15.98% of ANTX.
The largest institutional holders are Vivo Capital, LLC (8.36%), Commodore Capital Lp (7.77%) and Millennium Management Llc (6.14%). Together, the top 10 institutions control 45.4% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their ANTX positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ANTX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Vivo Capital, LLC | 3.15M | 8.36% | 0.0% |
| Commodore Capital Lp | 2.93M | 7.77% | +25.7% |
| Millennium Management Llc | 2.32M | 6.14% | +4.3% |
| Blackrock Inc. | 1.67M | 4.41% | +422.5% |
| Spruce Street Capital LP | 1.66M | 4.40% | 0.0% |
| Almitas Capital LLC | 1.47M | 3.89% | -0.7% |
| Vanguard Capital Management LLC | 1.24M | 3.28% | +22.5% |
| Adage Capital Partners GP L.L.C. | 1.00M | 2.65% | 0.0% |
| Citadel Advisors Llc | 952.00K | 2.52% | +513.3% |
| Boxer Capital Management, LLC | 749.03K | 1.98% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ANTX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 853.02K | 2.26% |
| iShares Trust-iShares Russell 2000 ETF | 594.04K | 1.57% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 360.11K | 0.95% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 289.23K | 0.77% |
| iShares Trust-iShares Russell 2000 Value ETF | 193.39K | 0.51% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 96.51K | 0.26% |
| iShares Trust-iShares Micro-Cap ETF | 88.27K | 0.23% |
| SCHWAB CAPITAL TRUST-Schwab Small-Cap Index Fund | 64.22K | 0.17% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 57.92K | 0.15% |
| Quantitative Master Series LLC-Master Small Cap Index Series | 49.47K | 0.13% |
Frequently asked questions
Who is the largest shareholder of AN2 Therapeutics?
Vivo Capital, LLC is the largest institutional shareholder of ANTX, owning 8.36% of shares outstanding (3.15M shares) as of its latest 13F filing.
What percentage of AN2 Therapeutics is owned by institutions?
Institutions own about 76.9% of ANTX shares and 91.5% of the public float.
How much of AN2 Therapeutics do insiders own?
Insiders, such as officers and directors, own about 15.98% of ANTX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.